Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 27 November 2020, 21:05 HKT/SGT
Share:
    

Source: Eisai
AbbVie and Eisai Announce an approval for additional indication of HUMIRA
A fully Human Anti-TNFalpha Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world

TOKYO, Nov 27, 2020 - (JCN Newswire) - AbbVie GK and Eisai Co., Ltd. today announced an approval of additional indication of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for the treatment of pyoderma gangrenosum (hereafter "PG"). HUMIRA was granted orphan drug designation for the treatment of PG in 2019. This indication counts for HUMIRA's 12th indication in Japan and makes HUMIRA the world's first drug indicated for the treatment of PG.

This approval of the additional indication is based on the data from the Japanese phase III clinical trial(1) conducted in Japanese patients. This study was conducted to evaluate the efficacy and safety of HUMIRA targeting the patients with active ulcers in Japan who were diagnosed with PG but were not sufficiently effective with local treatment, or who were judged to be unsuitable for local treatment. The proportion of patients achieving at 100 (targeted PG ulcer healed) of the target pyoderma gangrenosum ulcer area reduction (PG Area Reduction: PGAR) at Week 26 of administration, which is the primary endpoint of this trial, was 54.5% (12 of 22 patients)1. The most common adverse drug reactions in patients receiving HUMIRA were skin bacterial infection(1).

PG is an inflammatory skin disease that rapidly progresses after its onset and is classified into the following 5 types: ulcerative type, bullous type, pustular type, vegetative type, and a type that develops around a stoma(2). In ulcerative PG, the most common type, appears as painful, pustules, papules and nodules in the lower extremities, especially in the lower legs, and efferently expands to form raised ulcer lesions with infiltration on the margins(3). The ulceration accompanied by intense pain and is known to cause serious effects on patients' quality of life (QOL)(4). Although the pathogenic mechanism of PG is not fully understood, it is reported that approximately 20-30% of PG cases are caused by a slight injury or an external stimulus(5). PG mostly affects people in their 50s to 70s, and its incidence is reported to be 3.0 per million/year in Japan(6).

AbbVie and Eisai are committed to further contribute to the improvement of QOL of many more patients by making efforts to promote the appropriate use of HUMIRA, including its use for this indication, and to provide information on HUMIRA.

(1) ClinicalTrials.gov Identifier: NCT03311464. Unpublished data on file.
(2) Yamamoto T: J Dermatol, 130(6), 1439-1448, 2020
(3) Idemitsu T. Medical diseases seen in 110 cases of skin symptoms: 7(4), 138-139, 2018
(4) Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, Mason JM, Walton S, Johnston GA Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team.. 2015 Jun 12; 350: h2958. doi: 10.1136/bmj.h2958.
(5) Callen JP, Jackson JM: Pyoderma gangrenosum: an update,  Rheum Dis Clin North Am, 2007; 33: 787--802.
(6) Yamamoto T: J Dermatol, 46: e145-e146, 2019



Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 26, 2021 10:58 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time
Jan 12, 2021 11:37 HKT/SGT
Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium
Dec 18, 2020 12:09 HKT/SGT
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
Dec 17, 2020 11:47 HKT/SGT
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR
Dec 11, 2020 09:43 HKT/SGT
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
Dec 4, 2020 11:17 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at 43rd Annual San Antonio Breast Cancer Symposium
Nov 30, 2020 13:04 HKT/SGT
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
Nov 30, 2020 10:16 HKT/SGT
Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
Nov 18, 2020 19:11 HKT/SGT
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2020 for Seventh Time
Nov 18, 2020 19:00 HKT/SGT
Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: